Introduction
Viz.ai is a San Francisco-based company founded in 2016 that builds AI-powered care coordination software for hospitals. Chris Mansi serves as chief executive officer. Where many medical AI products focus on helping a single clinician interpret an individual study, Viz.ai’s model emphasizes speed across the entire care team: detecting critical findings on imaging studies and immediately notifying the specialists who need to act, reducing the delays that accumulate when scans sit in a queue waiting for manual review.
The company became widely known in stroke care, where minutes between scan and treatment materially affect patient outcomes, but its platform logic applies to other time-sensitive pathways as well. For Brel readers, Viz.ai is a useful example of AI embedded in operational workflow rather than positioned purely as a diagnostic adjunct.
Care coordination AI occupies a different adoption path from diagnostic AI that requires separate CPT billing: hospitals often justify Viz.ai on operational metrics — door-to-needle time, transfer coordination, specialist response — rather than on per-scan reimbursement alone.
What the company does
Viz.ai’s platform connects to hospital imaging systems, applies AI models to detect findings associated with urgent conditions, and pushes structured alerts to relevant clinicians’ mobile devices along with imaging context. The intent is to collapse the time between when a scan is acquired and when the right specialist begins evaluation — a bottleneck that has little to do with model accuracy and everything to do with hospital communication infrastructure. Viz.ai sells this as care coordination software with AI detection at its core, not as a standalone radiology workstation tool.
Who it serves
Viz.ai sells primarily to hospital systems and stroke centers that measure door-to-treatment times and need operational improvements beyond hiring additional overnight radiology coverage. Buyers are often clinical operations leaders and neurology or emergency medicine departments rather than radiology IT alone, because the product’s value proposition spans detection, notification, and team mobilization. The appointment of Jallel Harrati as chief revenue officer, announced on Viz.ai’s news page, signals continued investment in enterprise sales capacity as the company expands its hospital footprint.
Company background
Viz.ai was founded in 2016 in San Francisco by Chris Mansi, who remains CEO. The company grew during a period when FDA clearance pathways for clinical decision support software were becoming better understood, and when hospitals faced increasing pressure to reduce treatment delays for stroke and other acute conditions. Viz.ai raised venture funding and expanded from a stroke-focused product into a broader care-coordination platform, though stroke remains the category where the company is most frequently cited in clinical literature and hospital case studies.
Product and AI capabilities
Viz.ai applies deep-learning models to CT and other imaging modalities to flag suspected large-vessel occlusions and related findings, then routes alerts through a mobile-first interface designed for on-call specialists. The AI layer must meet sensitivity expectations appropriate for emergency triage — false negatives carry serious clinical risk — while the coordination layer must integrate with hospital paging, EHR, and imaging archive systems without adding friction that clinicians will bypass. That combination of clinical AI and workflow software is harder to replicate than a standalone algorithm, and it is central to Viz.ai’s competitive positioning.
Because Viz.ai’s value depends on notification speed and care-team response, implementation success is as much an organizational change management problem as a model performance problem. Hospitals that treat Viz.ai as a radiology-only purchase often underperform relative to those that embed it in stroke committee protocols and emergency department workflows.
Key developments
2016: Viz.ai founded in San Francisco; Chris Mansi is CEO. 2026: Viz.ai announced the appointment of Jallel Harrati as chief revenue officer, per the company’s official news release. Brel did not retain a separate supporting source for this profile because a previously cited third-party author page could not be verified.
Why it matters
Viz.ai matters because it demonstrates a category of healthcare AI where the primary value is operational — minutes saved, specialists notified, teams mobilized — rather than incremental improvement in diagnostic accuracy alone. That framing changes how hospital buyers evaluate ROI: the question is not only whether the model performs well on a test set but whether the hospital’s stroke or PE pathway actually runs faster after deployment. Viz.ai is also a useful contrast to digital pathology and precision medicine companies in the same healthcare AI sector, where reimbursement and clinical adoption timelines follow different logic.
Sector context
Viz.ai sits in Brel’s AI in healthcare coverage under care coordination and acute workflow AI, distinct from diagnostic imaging companies such as Butterfly Network (handheld ultrasound) or cardiology analysis vendors such as HeartFlow and Cleerly. Readers comparing deployment models should note that Viz.ai integrates into hospital communication workflows, while point-of-care imaging and ambulatory documentation tools sell on different clinical economics.
Sources and references
Viz.ai official news release on Jallel Harrati CRO appointment and company website.
- Viz.ai — Jallel Harrati appointed chief revenue officer (viz.ai)
- Viz.ai — Company website (viz.ai)